Equities research analysts expect GW Pharmaceuticals PLC (NASDAQ:GWPH) to report earnings per share (EPS) of ($1.39) for the current fiscal quarter, Zacks Investment Research reports. Two analysts have made estimates for GW Pharmaceuticals PLC’s earnings. The highest EPS estimate is ($0.09) and the lowest is ($2.12). GW Pharmaceuticals PLC reported earnings of ($0.89) per share during the same quarter last year, which would indicate a negative year over year growth rate of 56.2%. The company is scheduled to report its next earnings results on Monday, December 4th.

According to Zacks, analysts expect that GW Pharmaceuticals PLC will report full-year earnings of ($5.99) per share for the current fiscal year, with EPS estimates ranging from ($6.66) to ($5.04). For the next year, analysts anticipate that the firm will post earnings of ($6.43) per share, with EPS estimates ranging from ($6.96) to ($6.13). Zacks’ earnings per share averages are a mean average based on a survey of sell-side research analysts that that provide coverage for GW Pharmaceuticals PLC.

GW Pharmaceuticals PLC (NASDAQ:GWPH) last announced its earnings results on Monday, August 7th. The biopharmaceutical company reported ($2.07) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.73) by ($0.34). GW Pharmaceuticals PLC had a negative net margin of 1,384.41% and a negative return on equity of 28.80%. The firm had revenue of $3.14 million for the quarter, compared to the consensus estimate of $2.10 million. During the same period in the prior year, the business earned ($0.05) EPS.

A number of equities research analysts recently commented on the company. Zacks Investment Research cut GW Pharmaceuticals PLC from a “hold” rating to a “sell” rating in a research note on Thursday, July 6th. ValuEngine raised GW Pharmaceuticals PLC from a “sell” rating to a “hold” rating in a research note on Wednesday, June 21st. Goldman Sachs Group, Inc. (The) reissued a “neutral” rating and issued a $124.00 target price on shares of GW Pharmaceuticals PLC in a research note on Friday, October 6th. Maxim Group set a $135.00 target price on GW Pharmaceuticals PLC and gave the company a “buy” rating in a research note on Monday, August 7th. Finally, Cantor Fitzgerald set a $208.00 target price on GW Pharmaceuticals PLC and gave the company a “buy” rating in a research note on Tuesday, August 8th. One research analyst has rated the stock with a sell rating, four have given a hold rating, five have given a buy rating and one has issued a strong buy rating to the company. The company has an average rating of “Buy” and a consensus target price of $143.05.

ILLEGAL ACTIVITY WARNING: This story was first published by American Banking News and is owned by of American Banking News. If you are reading this story on another site, it was illegally copied and reposted in violation of U.S. & international copyright law. The correct version of this story can be read at https://www.americanbankingnews.com/2017/10/17/analysts-expect-gw-pharmaceuticals-plc-gwph-to-post-1-39-eps.html.

Several institutional investors and hedge funds have recently made changes to their positions in the company. IHT Wealth Management LLC raised its position in GW Pharmaceuticals PLC by 18.0% during the 2nd quarter. IHT Wealth Management LLC now owns 656 shares of the biopharmaceutical company’s stock worth $108,000 after purchasing an additional 100 shares during the last quarter. Advisor Group Inc. raised its position in GW Pharmaceuticals PLC by 10.7% during the 2nd quarter. Advisor Group Inc. now owns 1,500 shares of the biopharmaceutical company’s stock worth $130,000 after purchasing an additional 145 shares during the last quarter. BNP Paribas Arbitrage SA bought a new position in GW Pharmaceuticals PLC during the 2nd quarter worth $163,000. Blair William & Co. IL bought a new position in GW Pharmaceuticals PLC during the 1st quarter worth $207,000. Finally, Ameriprise Financial Inc. bought a new position in GW Pharmaceuticals PLC during the 1st quarter worth $230,000. Institutional investors own 75.06% of the company’s stock.

Shares of GW Pharmaceuticals PLC (GWPH) traded down 0.40% on Tuesday, reaching $110.81. The company had a trading volume of 163,218 shares. The company has a 50-day moving average price of $107.97 and a 200-day moving average price of $107.72. The firm’s market cap is $2.81 billion. GW Pharmaceuticals PLC has a one year low of $92.65 and a one year high of $136.95.

About GW Pharmaceuticals PLC

GW Pharmaceuticals plc is a biopharmaceutical company focused on developing and commercializing therapeutics from its cannabinoid product platform in a range of disease areas. The Company’s lead cannabinoid product candidate is Epidiolex, which is a liquid formulation of pure plant-derived cannabidiol (CBD).

Get a free copy of the Zacks research report on GW Pharmaceuticals PLC (GWPH)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for GW Pharmaceuticals PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GW Pharmaceuticals PLC and related companies with MarketBeat.com's FREE daily email newsletter.